Activity

Main Activities

  • Multi-omics data – Generate multi-layered data by measuring genomic, epigenomic, proteomic, metabolomic, and immune signals from healthy donors, and patients with pancreatic cancer, Alzheimer disease, and metabolic liver diseases.
  • Build generic algorithmic technologies for identification of multi-omics biomarkers – Multiple efforts are being combined to establish an infrastructure for merging data obtained from various modalities and testing methods performed on the same samples. This enables the implementation of algorithms and deep neural networks to conduct multi-omics prediction.
  • Coordinating the production and flow of information – The consortium is working on defining a unified architecture for data collection interfaces and facilitating the transfer of information across all partners. They are also coordinating the collection of data (including samples and tests) and determining the responsibilities of each partner.
  • Building shared data sets – fusing the results of different omics data that measure different biomarkers and which will be measured by different members working on different modalities and liquid biopsy sensing technologies.
  • Clinical validation – running tests on verified clinical samples to validate the biomarkers identification platforms and their implementation into sensing devices.
  • Analysis and insights – Generating insights for Identification of novel liquid biopsy-based multi omics biomarkers that will be used as a basis for the development of future products.
  • Multi-omics sensors – Development of modular and disease agnostic sensors to detect combinations of markers with high sensitivity and specificity.

 

Work Groups

LIQUIDBX Work Groups

In order to meet the objectives, the LIQUIDBX participants are organized into four major work groups, which are responsible for:

Work Group 1

Bio-samples & clinical data management

Work Group 2

Multi-Omics sensors technologies development

Work Group 3

Multi-omics data analysis and algorithm development

Work Group 4

Single Omics technology development and data generations

Work Process

The LIQUIDBX operation

Click on image to enlarge

WG1 – Bio-samples & Clinical data management

  • Collect bio-samples and complimentary clinical data for the three clinical demonstrators
  • Standardization of the collection conditions (volume, treatment, sample type, preservation conditions).
  • Managing the use of bio-samples in order to allow maximum coordination between the partners, for optimal usage of bio-samples
  • Preparing contrived samples for monitoring, and enhancing technology development, and supervising blinded testing. 

WG4 – Single Omics data generators

  • Develop highly sensitive single omics methods for detecting disease-associated molecules and signals across different platforms to support sensitive and specific detection of extremely low signals at the pre-symptomatic stage. Selection and validation of technologies that produce clinically meaningful data
  • Standardization of the measurements across all omics & technologies
  • Provide high quality, reproducible data to the computational group.
  • Validate biomarkers in blinded testing

WG3 – Computational platform, Data Science and Algorithms 

  • Creating a generic, and available cloud-based solution that accepts complex, and often missing data to produce an optimal collection of biomarkers in a disease agnostic manner.
  • Normalization of data from different sources
  • Developing tools for multi omics data integration while dealing with sparse and missing data at the intra and inter sample levels.
  • Generation of highly interpretive models so that key features are translated into biomarkers
  • Generate an accessible cloud computational platform for data sharing and identification of biomarkers

WG2 – Multi-omics sensing technologies for point of care usage

  • From lab to POC: Develop flexible and modular sensors to transform complex and costly single-omics technologies into simple point of care sensing devices
  • Multi omics on a chip: easily integrated and combinatorial “mix & match” microfluidic based sensors
  • Combine single-omics sensing technologies into a unified multi-omics measuring device
  • Machine learning analysis of data from the multi omics sensing device
  • Validate single and multi omics sensing on clinically relevant samples

Core Multi Omics modalities:

The LIQUIDBX consortium is developing an infrastructure for the development of generic technologies for the identification and detection of biological markers and their integration into modular multi omics, and point of care compatible sensors for the early detection of diseases. The consortium will generate data  at the genomic, transcriptomic, epigenomic, metabolic, proteomic, and immune systems levels,the computational tools for its integration and interpretation, and the sensing technologies for implementing multi omics markers in accessible point of care devices.  In our work in the consortium, we will focus our research on the following core multi-omics modalities:

  1. Proteomics -plasma mass spectrometry
  2. cfDNA – targeted and whole genome cell free DNA sequencing
  3. cfRNA – cell free RNA sequencing
  4. cfDNA Methylation analysis
  5. cfChromatin – cell free Chromatin immunoprecipitation and sequencing
  6. Blood cells analysis
  7. Mitochondrial function analysis
  8. Immune cells transcriptomics

Demonstrators:

The LIQUIDBX technology platform is being developed, verified, and tested through three distinct demonstrators by our consortium members. These demonstrators were selected based on specific criteria, including their potential for clinical significance and impact on human health, a large untapped market, interest from industrial companies, and our access to relevant biological samples for research and verification.

The three demonstrators are:

  1. Pancreatic cancer (95% fatality rate with no available solutions for early detection)
  2. NAFLD   & NASH  (fatty liver affects nearly 30% of the population. No current solution for early detection)
  3. Alzheimer’s disease (affects a high percentage of the population. No current solution for early detection)

Expected Deliverables

Period 1

  • A transparent system for managing biological samples
  • Protocols for collection and preservation for optimal use of bodily fluids by many technologies.
  • Unified biological standards for training and evaluation
  • Improvement of single omics technologies for maximal sensitivity and specificity as required for early detection
  • Cloud infrastructure for receiving and processing the various omics data
  • An array of cloud based algorithms for multi-omics data processing
  • Sensors with sufficient sensitivity and modularity to allow flexible development of products that allow multi omics-based early detection at the point of care.

Period 2

  • Generation of Multi-omics data – Generate data from all omics on at least 100 samples for each of the tested diseases and a complementary healthy cohort
  • Integrated data – for the purpose of identifying the complex biomarkers
  • Multi-omics POC sensing platform ready
  • Modular sensors capable of measuring multi-omics at the point of care
  • Identification of complex biomarkers for the target diseases that are compatible with point of care sensing.
  • Validation of the biomarkers and the sensors for detecting the relevant diseases
  • Improved algorithms for working on multi-omics to find complex biomarkers

Copyright 2023 LIQUIDBX – All Rights Reserved

Produced by Webzilla

Skip to content